CTT Pharmaceutical names Zhanna Kelley as auditor

Holt & Patterson said its resignation was not due to disagreements over accounting practices or anything in a company report.

Available on EDGAR 10/30/2026 - 01:05 PM EDT Accepted by SEC EDGAR 10/30/2026 - 01:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. signed an engagement letter with Zhanna Kelley, CPA on October 27, 2026, as the company’s PCAOB auditor moving forward. Its prior certifying public accountant, Holt & Patterson, had resigned and confirmed that the resignation was not due to a disagreement concerning the company’s accounting practices or anything in a company report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

certifying public accountant, PCAOB Auditor, engagement letter

3 terms

certifying public accountant financial

"our prior certifying public accountant resigned"

PCAOB Auditor regulatory

"as the Company’s PCAOB Auditor moving forward"

An PCAOB auditor is an independent accountant registered with the Public Company Accounting Oversight Board who inspects and signs off on a public company's financial statements. Think of them as a certified safety inspector for a company's books: their work gives investors confidence that financial reports are accurate and follow required rules, reducing the chance of undisclosed problems and helping people decide whether to buy, hold, or sell stock.

engagement letter financial

"signed an engagement letter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is CTTH's new auditor?

CTT Pharmaceutical Holdings, Inc. signed an engagement letter with Zhanna Kelley, CPA, as its PCAOB auditor moving forward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001035422false00010354222026-10-272026-10-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2026

CTT PHARMACEUTICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Florida		333-292497		90-1253984
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1646 W Snow Ave. Suite 138 Tampa, FL. 33606 

(Address of Principal Executive Offices) (Zip Code) 

813-606-0060 

(Registrant’s Telephone Number, Including Area Code) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) : As previously reported on Form 8-K filed October 7, 2026, Holt & Patterson, our prior certifying public accountant resigned. Such firm confirmed that their resignation was not due to any disagreement on any matter related to our accounting practices or anything contained in a report issued by us.  On October 27, 2026, CTT Pharmaceutical Holdings, Inc. signed an engagement letter with  Zhanna Kelley, CPA as the Company’s PCAOB Auditor moving forward.

Item 9.01 Financial Statements and Exhibits.

(b) Exhibits

Exhibit		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CTT PHARMACEUTICAL HOLDINGS, INC.
	(Registrant)
Date: 10/27/2026	By:	/s/ Ryan Khouri
	Name:	Ryan Khouri
	Title:	Chief Executive Officer (Principal Executive, Financial and Accounting Officer)

3

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 12.9 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 8.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB